Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents.

Treatment of Candida krusei fungemia can be problematic. We describe a 44-year-old critically ill, non-immunocompromised patient who had persistent Candida krusei fungemia complicated with septic thrombophlebitis of the inferior vena cava. Successful treatment was achieved by parenteral caspofungin followed by prolonged oral voriconazole. Persistent fungemia in the face of ongoing antifungal therapy and prompt removal of central line should alert physicians to the diagnosis of septic thrombophlebitis. Though combined therapy with amphotericin B and surgical intervention probably remains the treatment of choice, prolonged new antifungal agents, which have better efficacy, tolerability and bioavailability, may be a useful alternative where the central veins are relatively inaccessible or the patient is at high operative risk.

[1]  T. Peláez,et al.  Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. , 2005, The Journal of antimicrobial chemotherapy.

[2]  B. Barlogie,et al.  Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[5]  J. Graybill,et al.  In Vitro Activity of Caspofungin against Candida albicans Biofilms , 2002, Antimicrobial Agents and Chemotherapy.

[6]  B. Wickes,et al.  In Vitro Pharmacodynamic Properties of Three Antifungal Agents against Preformed Candida albicans Biofilms Determined by Time-Kill Studies , 2002, Antimicrobial Agents and Chemotherapy.

[7]  J. Reekers,et al.  Prospective Study of Color Duplex Ultrasonography Compared with Contrast Venography in Patients Suspected of Having Deep Venous Thrombosis of the Upper Extremities , 2002, Annals of Internal Medicine.

[8]  M. Ghannoum,et al.  Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins , 2002, Antimicrobial Agents and Chemotherapy.

[9]  M. Pfaller,et al.  Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000 , 2002, Journal of Clinical Microbiology.

[10]  J. Rex,et al.  All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  B. Wickes,et al.  Biofilms of Candida albicans and their associated resistance to antifungal agents. , 2001, American clinical laboratory.

[12]  G. Bodey,et al.  Candida krusei fungemia. An escalating serious infection in immunocompromised patients. , 2000, Archives of internal medicine.

[13]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[14]  F. Vermassen,et al.  Management of candidal thrombophlebitis of the central veins: case report and review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Delcore,et al.  Thrombolytic therapy for catheter-related thrombosis. , 1993, American journal of surgery.

[16]  G. Bodey,et al.  Azole antifungal agents. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Anand Vk,et al.  Thrombophlebitis of the jugular vein. , 1987 .

[18]  M. Topiel,et al.  Treatment of silastic catheter-induced central vein septic thrombophlebitis. , 1986, The American journal of the medical sciences.

[19]  R. Arbeit,et al.  Central Venous Septic Thrombophlebitis—The Role of Medical Therapy , 1985, Medicine.

[20]  E. Pollak,et al.  Subclavian‐Axillary Venous Thrombosis: Role of Noninvasive Diagnostic Methods , 1980, Southern medical journal.

[21]  J. Norante,et al.  Thrombophlebitis of the internal jugular vein secondary to pharyngitis. , 1980, Archives of otolaryngology.

[22]  D. Maki,et al.  Management of septic thrombosis of the inferior vena cava caused by Candida. , 1978, Archives of surgery.

[23]  A. Munster Septic thrombophlebitis. A surgical disorder. , 1974, JAMA.

[24]  J. Wingard,et al.  Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.